a Department of Urology , First Affiliated Hospital of Dalian Medical University , Dalian , China.
b Department of Pathology and Laboratory Medicine , Indiana University School of Medicine , Indianapolis , IN , USA.
Expert Rev Anticancer Ther. 2019 Feb;19(2):169-175. doi: 10.1080/14737140.2019.1548939. Epub 2018 Nov 29.
: Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behavior. In this review, we summarize the current progression on pRCC in molecular level. Our findings highlight the need for molecular markers to accurately subtype pRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. This review highlights the need for molecular markers to accurately subtype PRCC and may lead to the development of more targeted agents and better patient stratification in clinical trials for pRCC. : There are mainly two subtypes of pRCC based on histology. However, little is known about the genetic characterization of the sporadic forms of pRCC and there are currently no standard forms of therapy for patients with advanced disease. Both MET inhibitors and immunotherapy may be effective in advanced pRCC treatment. Therefore, understanding the molecular basis of pRCC and identifying the main goal of treatment is crucial for the selection of the best strategy.
: 乳头状肾细胞癌（pRCC）是一种重要的肾癌亚型，其病理分类存在问题，临床行为具有高度可变性。在这篇综述中，我们总结了 pRCC 在分子水平上的最新进展。我们的研究结果强调了需要分子标志物来准确地下 pRCC 亚型，并可能导致开发更有针对性的药物，并在临床试验中更好地对 pRCC 患者进行分层。这篇综述强调了需要分子标志物来准确地下 pRCC 亚型，并可能导致开发更有针对性的药物，并在临床试验中更好地对 pRCC 患者进行分层。: 根据组织学，pRCC 主要有两种亚型。然而，对于散发性 pRCC 的遗传特征知之甚少，目前也没有晚期患者的标准治疗方法。MET 抑制剂和免疫疗法在晚期 pRCC 治疗中可能都有效。因此，了解 pRCC 的分子基础和确定治疗的主要目标对于选择最佳策略至关重要。
